Is Shape of Aβ an Early Blood Biomarker for Alzheimer’s?
between 2000 and 2002 from ESTHER, a population-based longitudinal cohort of nearly 10,000 healthy older
378 RESULTS
You searched Esther
Sort By:
between 2000 and 2002 from ESTHER, a population-based longitudinal cohort of nearly 10,000 healthy older
strengthen the rationale for blocking the tau-fyn association as a therapeutic approach.—Esther Landhuis None
story).—Esther Landhuis None Immune Related Microglia/Astrocyte Growth Factors and Growth Factor Receptors
the gene contributes to AD pathogenesis, Cruchaga told Alzforum.—Esther Landhuis None Alzheimer's
told Alzforum.—Esther Landhuis None Alzheimer's Disease Imaging ApoE
microglia.—Esther Landhuis None Alzheimer's Disease Amyloid Immune Related Microglia/Astrocyte TREM2
to the list of potential mechanisms that go awry in aging and AD.—Esther Landhuis None
occur 15 to 20 years before symptoms,” she said. “That gives us a good therapeutic window.”—Esther
investigate the mechanisms for generation of the N-terminal fragments and their potential functions.—Esther
system waste products,” the authors write.—Esther Landhuis None
motion, David Brody of Washington University, St. Louis, Missouri, told Alzforum.—Esther Landhuis None
consider testing them in disease models, she said.—Esther Landhuis None
disease.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3612 Alzheimer's Disease Aβ Tau
sequencing-based platforms,” Cookson said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3604
LilrB2 sits near apolipoprotein E (the top AD risk gene) on chromosome 19.—Esther Landhuis None